Unbound (bioavailable) IGF1 enhances somatic growth

SUMMARY Understanding insulin-like growth factor-1 (IGF1) biology is of particular importance because, apart from its role in mediating growth, it plays key roles in cellular transformation, organ regeneration, immune function, development of the musculoskeletal system and aging. IGF1 bioactivity is modulated by its binding to IGF-binding proteins (IGFBPs) and the acid labile subunit (ALS), which are present in serum and tissues. To determine whether IGF1 binding to IGFBPs is necessary to facilitate normal growth and development, we used a gene-targeting approach and generated two novel knock-in mouse models of mutated IGF1, in which the native Igf1 gene was replaced by Des-Igf1 (KID mice) or R3-Igf1 (KIR mice). The KID and KIR mutant proteins have reduced affinity for the IGFBPs, and therefore present as unbound IGF1, or ‘free IGF1’. We found that both KID and KIR mice have reduced serum IGF1 levels and a concomitant increase in serum growth hormone levels. Ternary complex formation of IGF1 with the IGFBPs and the ALS was markedly reduced in sera from KID and KIR mice compared with wild type. Both mutant mice showed increased body weight, body and bone lengths, and relative lean mass. We found selective organomegaly of the spleen, kidneys and uterus, enhanced mammary gland complexity, and increased skeletal acquisition. The KID and KIR models show unequivocally that IGF1-complex formation with the IGFBPs is fundamental for establishing normal body and organ size, and that uncontrolled IGF bioactivity could lead to pathological conditions.

[1]  Chengyu Liu,et al.  Unbound (bioavailable) IGF1 enhances somatic growth , 2011, Journal of Cell Science.

[2]  S. Yakar,et al.  Sex‐specific regulation of body size and bone slenderness by the acid labile subunit , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[3]  G. Brabant,et al.  GH/IGF-I Regulation in Obesity – Mechanisms and Practical Consequences in Children and Adults , 2010, Hormone Research in Paediatrics.

[4]  A. Tamakoshi,et al.  Time spent walking or exercising and blood levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3): A large-scale cross-sectional study in the Japan Collaborative Cohort study. , 2009, Asian Pacific journal of cancer prevention : APJCP.

[5]  H. V. van Duyvenvoorde,et al.  Human Acid-Labile Subunit Deficiency: Clinical, Endocrine and Metabolic Consequences , 2009, Hormone Research in Paediatrics.

[6]  M. Bouxsein,et al.  Serum IGF‐1 Determines Skeletal Strength by Regulating Subperiosteal Expansion and Trait Interactions , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[7]  M. Bouxsein,et al.  Serum complexes of insulin‐like growth factor‐1 modulate skeletal integrity and carbohydrate metabolism , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[8]  A. Efstratiadis,et al.  The hormonal action of IGF1 in postnatal mouse growth , 2008, Proceedings of the National Academy of Sciences.

[9]  M. Westwood,et al.  The IGF Axis and Placental Function , 2008, Hormone Research in Paediatrics.

[10]  Steven M. Tommasini,et al.  Genetic randomization reveals functional relationships among morphologic and tissue-quality traits that contribute to bone strength and fragility , 2007, Mammalian Genome.

[11]  S. Yakar,et al.  The role of circulating IGF-I , 2002, Endocrine.

[12]  T. Ludwig,et al.  Diminished growth and enhanced glucose metabolism in triple knockout mice containing mutations of insulin-like growth factor binding protein-3, -4, and -5. , 2006, Molecular endocrinology.

[13]  O. Gavrilova,et al.  Recombinant human insulin-like growth factor-I treatment inhibits gluconeogenesis in a transgenic mouse model of type 2 diabetes mellitus. , 2006, Endocrinology.

[14]  M. Bouxsein,et al.  The ternary IGF complex influences postnatal bone acquisition and the skeletal response to intermittent parathyroid hormone. , 2006, The Journal of endocrinology.

[15]  J. Frystyk.  Aging somatotropic axis: mechanisms and implications of insulin-like growth factor-related binding protein adaptation. , 2005, Endocrinology and metabolism clinics of North America.

[16]  D. Leroith,et al.  The role of the growth hormone/insulin-like growth factor axis in tumor growth and progression: Lessons from animal models. , 2005, Cytokine & growth factor reviews.

[17]  O. Gavrilova,et al.  The growth hormone-insulin like growth factor axis revisited: lessons from IGF-1 and IGF-1 receptor gene targeting , 2005, Pediatric Nephrology.

[18]  J. Heinrich,et al.  Deficiency of the circulating insulin-like growth factor system associated with inactivation of the acid-labile subunit gene. , 2004, The New England journal of medicine.

[19]  M. Bouxsein,et al.  Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1-deficient mice. , 2004, The Journal of clinical investigation.

[20]  R. Kaaks.  Nutrition, insulin, IGF-1 metabolism and cancer risk: a summary of epidemiological evidence. , 2004, Novartis Foundation symposium.

[21]  H. Orskov,et al.  A highly sensitive and specific assay for determination of IGF-I bioactivity in human serum. , 2003, American journal of physiology. Endocrinology and metabolism.

[22]  N. Copeland,et al.  A highly efficient recombineering-based method for generating conditional knockout mutations. , 2003, Genome research.

[23]  S. Mohan,et al.  IGF-binding proteins are multifunctional and act via IGF-dependent and -independent mechanisms. , 2002, The Journal of endocrinology.

[24]  D. Leroith,et al.  Circulating levels of IGF-1 directly regulate bone growth and density. , 2002, The Journal of clinical investigation.

[25]  J. Frystyk,et al.  Liver-specific igf-1 gene deletion leads to muscle insulin insensitivity. , 2001, Diabetes.

[26]  R. Baxter.  Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities. , 2000, American journal of physiology. Endocrinology and metabolism.

[27]  D. Leroith,et al.  Insulin-like growth factor-I affects perinatal lethality and postnatal development in a gene dosage-dependent manner: manipulation using the Cre/loxP system in transgenic mice. , 1998, Molecular endocrinology.

[28]  M. Kaleko,et al.  Multivalent cations and ligand affinity of the type 1 insulin‐like growth factor receptor on P2A2‐LISN muscle cells , 1998, Journal of cellular physiology.

[29]  J. Carrasquillo,et al.  Biodistribution of 125I-labeled des(1-3) insulin-like growth factor I in tumor-bearing nude mice and its in vitro catabolism. , 1997, Cancer research.

[30]  J. Florini,et al.  The Mitogenic and Myogenic Actions of Insulin-like Growth Factors Utilize Distinct Signaling Pathways* , 1997, The Journal of Biological Chemistry.

[31]  R. Marcus,et al.  Effect of rhGH and rhIGF-I treatment on protein utilization in elderly women. , 1997, The American journal of physiology.

[32]  M. Savage,et al.  Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene. , 1996, The New England journal of medicine.

[33]  J. Rosen,et al.  Targeted expression of des(1-3) human insulin-like growth factor I in transgenic mice influences mammary gland development and IGF-binding protein expression. , 1996, Endocrinology.

[34]  R. Marcus,et al.  The effects of recombinant human insulin-like growth factor-I and growth hormone on body composition in elderly women. , 1995, The Journal of clinical endocrinology and metabolism.

[35]  葛谷 英嗣.  Insulin-like Growth Factor I (IGF-I) 治療 : 理論的背景と現状 , 1995 .

[36]  安子 内潟,et al.  妊娠時における糖尿病網膜症とInsulin-like growth factor I(IGF-I) , 1994 .

[37]  J. Beattie,et al.  Several insulin-like growth factor-I analogues and complexes of insulin-like growth factors-I and -II with insulin-like growth factor-binding protein-3 fail to mimic the effect of growth hormone upon lactation in the rat. , 1994, The Journal of endocrinology.

[38]  Y. Kyōgoku,et al.  Three-dimensional structure of human insulin-like growth factor-I (IGF-I) determined by 1H-NMR and distance geometry. , 2009, International journal of peptide and protein research.

[39]  Elizabeth J. Robertson,et al.  Role of insulin-like growth factors in embryonic and postnatal growth , 1993, Cell.

[40]  J. Wallace,et al.  Plasma clearance and tissue distribution of labelled insulin-like growth factor-I (IGF-I) and an analogue LR3IGF-I in pregnant rats. , 1993, The Journal of endocrinology.

[41]  M. Waters,et al.  of Insulin-Like Growth , 1993 .

[42]  J. Wallace,et al.  Production and characterization of recombinant insulin-like growth factor-I (IGF-I) and potent analogues of IGF-I, with Gly or Arg substituted for Glu3, following their expression in Escherichia coli as fusion proteins. , 1992, Journal of molecular endocrinology.

[43]  I. Campbell,et al.  Solution structure of human insulin-like growth factor 1: a nuclear magnetic resonance and restrained molecular dynamics study. , 1993, Biochemistry.

[44]  F. Ballard,et al.  IGF-I and the truncated analogue des-(1-3)IGF-I enhance growth in rats after gut resection. , 1991, The American journal of physiology.

[45]  S. E. Knowles,et al.  Plasma clearance and tissue distribution of labelled insulin-like growth factor-I (IGF-I), IGF-II and des(1-3)IGF-I in rats. , 1991, The Journal of endocrinology.

[46]  C. Bagley,et al.  Enhanced potency of truncated insulin-like growth factor-I (des(1-3)IGF-I) relative to IGF-I in lit/lit mice. , 1990, The Journal of endocrinology.

[47]  D. M. Crist,et al.  Diet and insulinlike growth factor I in relation to body composition in women with exercise-induced hypothalamic amenorrhea. , 1990, Journal of the American College of Nutrition.

[48]  J. Mcmurtry,et al.  Plasma clearance of chicken and human insulin-like growth factor-I and their association with circulating binding proteins in chickens. , 1990, The Journal of endocrinology.

[49]  R. Baxter,et al.  Structure of the Mr 140,000 growth hormone-dependent insulin-like growth factor binding protein complex: determination by reconstitution and affinity-labeling. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[50]  D. Underwood,et al.  The C region of human insulin-like growth factor (IGF) I is required for high affinity binding to the type 1 IGF receptor. , 1989, The Journal of biological chemistry.

[51]  J. Wallace,et al.  Insulin-like growth factor (IGF)-binding proteins inhibit the biological activities of IGF-1 and IGF-2 but not des-(1-3)-IGF-1. , 1989, The Biochemical journal.

[52]  R. Palmiter,et al.  Growth enhancement of transgenic mice expressing human insulin-like growth factor I. , 1988, Endocrinology.

[53]  J. Wallace,et al.  The bovine insulin-like growth factor (IGF) binding protein purified from conditioned medium requires the N-terminal tripeptide in IGF-1 for binding. , 1988, Biochemical and biophysical research communications.

[54]  F. Ballard,et al.  Specific binding of insulin-like growth factors 1 and 2 to the type 1 and type 2 receptors respectively. , 1988, The Biochemical journal.

[55]  J. Wallace,et al.  Natural and synthetic forms of insulin-like growth factor-1 (IGF-1) and the potent derivative, destripeptide IGF-1: biological activities and receptor binding. , 1987, Biochemical and biophysical research communications.